Digital repository of Slovenian research organisations

Search the repository
A+ | A- | Help | SLO | ENG

Query: search in
search in
search in
search in

Options:
  Reset


Query: "author" (Nežka Hribernik) .

1 - 10 / 20
First pagePrevious page12Next pageLast page
1.
Tumorji prebavil : Standardi in perspektive
2022, proceedings of peer-reviewed scientific conference contributions (domestic conferences)

Keywords: tumorji, sistemsko zdravljenje, nevroendokrini tumorji, metastatski rak, transplantacija, kemoradioterapija, radioterapija, lokalno napredovali rak, rehabilitacija, limfadenektomija, klinična prehrana, zborniki, elektronske knjige
Published in DiRROS: 16.01.2023; Views: 43; Downloads: 22
.pdf Full text (25,62 MB)
This document has many files! More...

2.
Novosti v sistemskem zdravljenju karcinoma požiralnika : klinični primer
Rozala Arko, Nežka Hribernik, 2022, published scientific conference contribution

Abstract: Rak požiralnika sodi med rake prebavil z najslabšo prognozo. V zadnjih letih pa se preživetje bolnikov z rakom požiralnika podaljšuje z vpeljavo novih oblik zdravljenja. Klinične študije so pokazale pomemben doprinos k izboljšanju preživetja ter časa do napredovanja bolezni z uporabo kombinirane kemoterapije z imunoterapijo pri bolnikih z razširjenim rakom požiralnika. Pri bolnikih po resekciji raka požiralnika pa na klinični pomembnosti pridobiva dopolnilno zdravljenje z nivolumabom. Kvalitetna obravnava bolnikov z rakom požiralnika je multidisciplinarna ter vključuje tako prehransko, kirurško, radio-terapevtsko, sistemsko ter paliativno obravnavo. Pričujoči prispevek nam poda primer bolnika z loko-regionalno boleznijo raka požiralnika, ki je post-operativno prejel dopolnilno terapijo z nivolumabom. Drugi primer pa opisuje bolnika z razširjeno boleznijo raka ezofagogastričnega stika, ki je prejel kombinirano kemoterapijo z imunoterapijo z nivolumabom.
Keywords: rak požiralnika, sistemsko zdravljenje, rak prebavil
Published in DiRROS: 12.01.2023; Views: 53; Downloads: 17
.pdf Full text (86,18 KB)

3.
Novosti v sistemskem zdravljenju karcinoma požiralnika
Nežka Hribernik, 2022, published scientific conference contribution

Abstract: Rak požiralnika je po incidenci in umrljivosti med desetimi najpogostejšimi raki in eden od rakov z najslabšo prognozo. V zadnjih letih so bile na področju specifičega sistemskega zdravljenja raka požiralnika stadija III in IV objavljene nove klinične raziskave, ki bodo na kratko predstavljene v tem prispevku. Poleg citostatskega zdravljenja je sedaj pri bolnikih z metastatsko obliko raka in visoko izraženostjo PD-L1 indicirano kombinirano sistemsko zdravljenje z kemoterapijo in zaviralcem imunskih nadzornih točk. Pri bolnikih po radikalnem zdravljenju s kemoradioterapijo in resekcijo, brez doseženega patološkega popolnega odgovora, pa je indicirano enoletno zdravljenje z nivolumabom.
Keywords: rak požiralnika, sistemsko zdravljenje, rak prebavil
Published in DiRROS: 10.01.2023; Views: 37; Downloads: 15
.pdf Full text (181,53 KB)

4.
Imunoterapevtski pristopi pri zdravljenju limfoproliferativnih bolezni
Marko Boc, 2022, other monographs and other completed works

Keywords: limfomi, imunoterapija, limfoproliferativne bolezni
Published in DiRROS: 17.11.2022; Views: 132; Downloads: 45
.pdf Full text (15,82 MB)
This document has many files! More...

5.
6.
Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients : a pilot study
Nežka Hribernik, Daniel T. Huff, Andrej Studen, Katarina Zevnik, Žan Klaneček, Hamid Emamekhoo, Katja Škalič, Robert Jeraj, Martina Reberšek, 2022, original scientific article

Abstract: Purpose: To develop quantitative molecular imaging biomarkers of immune-related adverse event (irAE) development in malignant melanoma (MM) patients receiving immune-checkpoint inhibitors (ICI) imaged with 18F-FDG PET/CT. Methods: 18F-FDG PET/CT images of 58 MM patients treated with anti-PD-1 or anti-CTLA-4 ICI were retrospectively analyzed for indication of irAE. Three target organs, most commonly affected by irAE, were considered: bowel, lung, and thyroid. Patient charts were reviewed to identify which patients experienced irAE, irAE grade, and time to irAE diagnosis. Target organs were segmented using a convolutional neural network (CNN), and novel quantitative imaging biomarkers - SUV percentiles (SUVX%) of 18F-FDG uptake within the target organs - were correlated with the clinical irAE status. Area under the receiver-operating characteristic curve (AUROC) was used to quantify irAE detection performance. Patients who did not experience irAE were used to establish normal ranges for target organ 18F-FDG uptake. Results: A total of 31% (18/58) patients experienced irAE in the three target organs: bowel (n=6), lung (n=5), and thyroid (n=9). Optimal percentiles for identifying irAE were bowel (SUV95%, AUROC=0.79), lung (SUV95%, AUROC=0.98), and thyroid (SUV75%, AUROC=0.88). Optimal cut-offs for irAE detection were bowel (SUV95%>2.7 g/mL), lung (SUV95%>1.7 g/mL), and thyroid (SUV75%>2.1 g/mL). Normal ranges (95% confidence interval) for the SUV percentiles in patients without irAE were bowel [1.74, 2.86 g/mL], lung [0.73, 1.46 g/mL], and thyroid [0.86, 1.99 g/mL]. Conclusions: Increased 18F-FDG uptake within irAE-affected organs provides predictive information about the development of irAE in MM patients receiving ICI and represents a potential quantitative imaging biomarker for irAE. Some irAE can be detected on 18F-FDG PET/CT well before clinical symptoms appear.
Keywords: melanoma, malignant melanoma, immune-checkpoint inhibitors, molecular imaging biomarkers
Published in DiRROS: 07.09.2022; Views: 139; Downloads: 56
.pdf Full text (9,65 MB)

7.
Zaviralci imunskih kontrolnih točk in imunsko pogojeni neželeni učinki
Nežka Hribernik, 2022, published scientific conference contribution

Keywords: imunoterapija, zaviralci imunskih nadzornih točk, neželeni učinki, multidisciplinarna obravnava
Published in DiRROS: 02.09.2022; Views: 154; Downloads: 71
.pdf Full text (226,36 KB)
This document has many files! More...

8.
Dnevnik zdravljenja z zdravilom regorafenib
Janja Ocvirk, Martina Reberšek, Neva Volk, Tanja Mesti, Marko Boc, Marija Ignjatović, Nežka Hribernik, 2022, dictionary, encyclopaedia, lexicon, manual, atlas, map

Keywords: kemoterapija, rak debelega črevesa in danke, gastrointestinalni tumorji
Published in DiRROS: 14.07.2022; Views: 369; Downloads: 94
.pdf Full text (2,48 MB)

9.
Klinični primer bolnika z BRAF V600 mutiranim, mejno resektabilnim kožnim melanomom in KLL : Elektronski vir
Karla Berlec, Nežka Hribernik, 2022, published scientific conference contribution

Keywords: melanom, rak kože, kemoterapija
Published in DiRROS: 11.04.2022; Views: 206; Downloads: 99
.pdf Full text (296,70 KB)

10.
Sistemsko zdravljenje melanomskih bolnikov z metastazami v centralnem živčnem sistemu : Elektronski vir
Nežka Hribernik, 2022, published scientific conference contribution

Keywords: melanom, rak kože, sistemsko zdravljenje
Published in DiRROS: 11.04.2022; Views: 238; Downloads: 89
.pdf Full text (429,44 KB)

Search done in 0.69 sec.
Back to top